SDCBP and prostate cancer: Syntenin-1 immunofluorescence was performed on non-malignant (PNT1a, PNT2) and prostate cancer cell lines (22RV1, DU-145, LNCaP) using mono-specific monoclonal Synt-3A11 and Synt-2C6 antibodies and showed two spatially distinct epitopes in prostate cell lines.